Derick H. M. Lau, MD, PhD

home / authors / derick-h-m-lau-md-phd

Articles

Adjuvant Treatment of Stage IB NSCLC: The Problem of Stage Subset Heterogeneity

Royce Calhoun, MD;Derick H. M. Lau, MD, PhD;David R. Gandara, MD

April 30th 2008

Stage IB non–small-cell lung carcinoma (NSCLC) represents a subset of early-stage, resectable NSCLC, usually treated with curative intent, but with historically modest 5-year survival rates ranging from 40% to 67% with surgical resection alone.[1,2] Disappointingly, modern adjuvant chemotherapy trials including stage IB patients have shown little evidence of chemotherapeutic benefit.

Gemcitabine in Combination With New Platinum Compounds: An Update

David. R. Gandara, MD;Martin J. Edelman, MD;Primo N. Lara, Jr, MD;Derick H. M. Lau, MD, PhD

March 3rd 2001

Combinations of gemcitabine (Gemzar) with cisplatin (Platinol) are among the most active new chemotherapy regimens developed for advanced non-small-cell lung cancer. Carboplatin (Paraplatin) is a platinum analog

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

David R. Gandara, MD;Martin Edelman, MD;Primo N. Lara, Jr, MD;Derick H. M. Lau, MD, PhD;Peter Roberts, MD;Bryan R. Leigh, MD

July 2nd 2000

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung

Gemcitabine/Carboplatin Combination Regimens: Importance of Dose Schedule

David R. Gandara, MD;Derick H. M. Lau, MD, PhD;Primo N. Lara, Jr, MD;Martin J. Edelman, MD

July 1st 2000

Platinum compounds, either cisplatin (Platinol) or carboplatin (Paraplatin), in combination with a number of new chemotherapeutic agents, have demonstrated improved response or survival compared to cisplatin alone or older